Earlier quoted context omitted.
Looking at the two papers (original, and updated) they only removed the Elgazzer paper but not the contested Shakhsi Niaee also mentioned in the Nature article. This is noteworthy because it's also the only other RCT to show strong effect on mortality (see Fig3 in the two papers). Original Marik, Kory paper Fig3 is here: https://pubmed.ncbi.nlm.nih.gov/34375047/#&gid=article-figur... Also, the Nature article is conce…
Sure that's a good point. But is mortality the appropriate clinical trial endpoint? Mortality rates are already low when following the NIH treatment guidelines, so it would take a large study population to discern any statistically significant effects. https://www.covid19treatmentguidelines.nih.gov/ In addition to mortality it probably makes sense to look at other endpoints such as patient reported symptoms, RT PCR t…
https://www.abs.gov.au/articles/covid-19-mortality-0
https://www.ajtmh.org/view/journals/tpmd/104/6/article-p2176...